CeriBell (NASDAQ:CBLL) CEO Sells $714,870.00 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 39,000 shares of CeriBell stock in a transaction on Monday, June 8th. The stock was sold at an average price of $18.33, for a total transaction of $714,870.00. Following the transaction, the chief executive officer directly owned 816,317 shares in the company, valued at approximately $14,963,090.61. This represents a 4.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, May 21st, Xingjuan Chao sold 6,030 shares of CeriBell stock. The stock was sold at an average price of $18.00, for a total transaction of $108,540.00.
• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total transaction of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.40, for a total transaction of $717,600.00.

CeriBell Trading Up 1.8%

Shares of NASDAQ CBLL opened at $18.47 on Friday. The company’s fifty day moving average is $18.98 and its 200-day moving average is $19.68. The stock has a market cap of $700.75 million, a price-to-earnings ratio of -11.33 and a beta of 0.84. CeriBell, Inc. has a twelve month low of $10.85 and a twelve month high of $24.33. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). The firm had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%. Equities research analysts predict that CeriBell, Inc. will post -1.69 EPS for the current year.

Analyst Upgrades and Downgrades

CBLL has been the topic of a number of recent analyst reports. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, May 27th. Canaccord Genuity Group cut their price objective on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

Institutional Investors Weigh In On CeriBell

Several institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its position in CeriBell by 15.3% in the 1st quarter. Bank of America Corp DE now owns 319,837 shares of the company’s stock valued at $5,863,000 after acquiring an additional 42,340 shares in the last quarter. Quantinno Capital Management LP lifted its position in CeriBell by 3.0% in the 1st quarter. Quantinno Capital Management LP now owns 140,347 shares of the company’s stock valued at $2,573,000 after acquiring an additional 4,119 shares in the last quarter. Sei Investments Co. lifted its position in CeriBell by 2.3% in the 1st quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock valued at $923,000 after acquiring an additional 1,125 shares in the last quarter. State of Wyoming bought a new stake in CeriBell in the 1st quarter valued at $62,000. Finally, KCM Capital Inc lifted its position in CeriBell by 40.0% in the 1st quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after acquiring an additional 400,000 shares in the last quarter.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.